Passage Bio (NASDAQ:PASG – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.
Profitability
This table compares Passage Bio and Achilles Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Passage Bio | N/A | -72.53% | -52.10% |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
Risk & Volatility
Passage Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Passage Bio | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Passage Bio currently has a consensus price target of $7.75, indicating a potential upside of 770.79%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 273.83%. Given Passage Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Passage Bio is more favorable than Achilles Therapeutics.
Valuation & Earnings
This table compares Passage Bio and Achilles Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Passage Bio | N/A | N/A | -$102.06 million | ($1.17) | -0.76 |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.65 |
Passage Bio is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 4.3% of Passage Bio shares are held by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
About Passage Bio
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.
